Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9614593 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1TSHRABCB11 | |
| SCHEMBL9614594 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1TSHRABCB11 | |
| SCHEMBL6467646 | 0.80 | EPHX1 (0.42) | ALDH1A1KMT2ATSHRADRA2APDE4A | |
| Lomustine SCHEMBL863570 | 0.75 | ADRA2A (0.83) | ALDH1A1KMT2AMEN1TSHRABCB11 | |
| SCHEMBL39462 | 0.74 | ADRA2A (0.40) | ALDH1A1KMT2ATSHRADRA2APDE4A | |
| SCHEMBL12506208 | 0.74 | ADRA2A (0.56) | ALDH1A1ADRA2APDE4AADRA1ASMN1; SMN2 | |
| SCHEMBL18917213 | 0.71 | TSHR (0.43) | ALDH1A1KMT2AMEN1TSHRADRA2A | |
| SCHEMBL1902755 | 0.71 | ADRA2A (0.42) | ALDH1A1KMT2AMEN1TSHRABCB11 | |
| Semustine SCHEMBL8980108 | 0.69 | ALDH1A1 (0.79) | ALDH1A1KMT2AMEN1TSHRABCB11 | |
| Carmustine SCHEMBL2047318 | 0.68 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1TSHRABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024256849-A1 | 4-PHENYLBUTYRIC ACID DERIVATIVES FOR USE IN THE TREATMENT OF FIBROSIS | PHENOTEC AG (CH) | 2024-12-19 | — | — | WO | claimed |
| EP-2673362-B1 | PLEXIN-B1 ANTAGONISTS AND USES THEREOF | Ruprecht-Karls-Universität Heidelberg (DE) | 2017-06-07 | — | — | EP | claimed |
| US-20160206579-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-07-21 | — | — | US | claimed |
| US-20260078219-A1 | Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof | ANP TECHNOLOGIES, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250195443-A1 | Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof | ANP TECHNOLOGIES, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250090586-A1 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2025-03-20 | — | — | US | disclosed |
| EP-4493219-A1 | POLYMER NANOAGGREGATE PHARMACEUTICAL COMPOSITION AND USE THEREOF | ANP Technologies, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2024256849-A1 | 4-PHENYLBUTYRIC ACID DERIVATIVES FOR USE IN THE TREATMENT OF FIBROSIS | PHENOTEC AG (CH) | 2024-12-19 | — | — | WO | disclosed |
| US-12076347-B2 | Methods for production of platelets from pluripotent stem cells and compositions thereof | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2024-09-03 | — | — | US | disclosed |
| WO-2023177629-A1 | POLYMER NANOAGGREGATE PHARMACEUTICAL COMPOSITION AND USE THEREOF | ANP TECHNOLOGIES, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230028239-A1 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2023-01-26 | — | — | US | disclosed |
| US-6949350-B1 | Chemosensitivity determination using phosphatidylserine | EVOTEC ANALYTICAL SYSTEMS GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | PHARMACIA CORPORATION | 2005-09-15 | — | — | US | disclosed |
| WO-2005059133-A2 | COMBINATION THERAPY ASSOCIATING A TGF-BRETA ANTAGONIST WITH A CHEMIOTHERAPEUTIC AGENT | ANTISENSE PHARMA GMBH (DE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005025620-A2 | COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS | PHARMACIA CORPORATION (US) | 2005-03-24 | — | — | WO | disclosed |
| WO-2001010416-A1 | METHOD OF DELIVERING A CHEMOTHERAPEUTIC AGENT TO A SOLID TUMOR | ALKERMES CONTROLLED THERAPEUTICS, INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| EP-0525188-B1 | LIPOSOME COMPOSITION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5252336-A | Good dispersibility; high stability; high encapsulation properties | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-12 | — | — | US | disclosed |
| EP-0525188-A1 | LIPOSOME COMPOSITION. | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-02-03 | — | — | EP | disclosed |
| WO-1991016040-A1 | LIPOSOME COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078219-A1 | Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof | HAO2, HRH1, PHB1 | ALDH1A1 1430/4885KMT2A 4473/4885MEN1 3435/4885 |
| US-20230028239-A1 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | THPO, PDGFRA, PDGFRB | ALDH1A1 1095/4885KMT2A 3809/4885MEN1 4499/4885 |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | NOS2, NOS1, NOS3 | ALDH1A1 995/4885KMT2A 718/4885MEN1 1356/4885 |
| US-20250195443-A1 | Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof | BRCA1, TP53, PRNP | ALDH1A1 4392/4885KMT2A 3735/4885MEN1 2420/4885 |
| US-20250090586-A1 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | THPO, PDGFRA, PDGFRB | ALDH1A1 1095/4885KMT2A 3809/4885MEN1 4499/4885 |
| US-12076347-B2 | Methods for production of platelets from pluripotent stem cells and compositions thereof | THPO, PDGFRA, PDGFRB | ALDH1A1 1095/4885KMT2A 3809/4885MEN1 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.